Dual targeting of EZH1 and EZH2 for the treatment of malignant rhabdoid tumors-Reference-Cited by-同舟云学术

Dual targeting of EZH1 and EZH2 for the treatment of malignant rhabdoid tumors

Published:2022-12 Issue: Volume:27 Page:14-25
ISSN:2372-7705
Container-title:Molecular Therapy - Oncolytics
language:en
Short-container-title:Molecular Therapy - Oncolytics

Author:

Shinohara Haruka,Sawado Rie,Nakagawa Makoto,Hattori Ayuna,Yamagata Kazutsune,Tauchi Kimiharu,Ito Jumpei,Kuwahara Yasumichi,Okuda Tsukasa,Ogawa Chitose,Kitabayashi Issay^ORCID

Funder

Daiichi Sankyo Company

Dainippon Sumitomo Pharma

National Cancer Center

Publisher

Elsevier BV

Subject

Pharmacology (medical),Cancer Research,Oncology,Molecular Medicine

Reference31 articles.

1. Alterations of the hSNF5/INI1 gene in central nervous system atypical teratoid/rhabdoid tumors and renal and extrarenal rhabdoid tumors;Biegel;Clin. Cancer Res.,2002

2. Clinicopathologic prognostic factors in childhood atypical teratoid and rhabdoid tumor of the central nervous system: a multicenter study;Dufour;Cancer,2012

3. Prognostic factors and survival in non-central nervous system rhabdoid tumors;Farber;J. Pediatr. Surg.,2017

4. Clinical and prognostic characteristics of 53 cases of extracranial malignant rhabdoid tumor in children. A single-institute experience from 2007 to 2017;Cheng;Oncologist,2019

5. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer;Versteege;Nature,1998

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PPARγ and C/EBPα enable adipocyte differentiation upon inhibition of histone methyltransferase PRC2 in malignant tumors;Journal of Biological Chemistry;2024-09

2. Population pharmacokinetics of total and unbound valemetostat and platelet dynamics in healthy volunteers and patients with non‐Hodgkin lymphoma;CPT: Pharmacometrics & Systems Pharmacology;2024-07-30

3. Chromatin remodellers as therapeutic targets;Nature Reviews Drug Discovery;2024-07-16

4. Targeting dependency on a paralog pair of CBP/p300 against de-repression of KREMEN2 in SMARCB1-deficient cancers;Nature Communications;2024-06-05

5. EZH2: The roles in targeted therapy and mechanisms of resistance in breast cancer;Biomedicine & Pharmacotherapy;2024-06